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ABSTRACT: 1H magnetic resonance spectroscopy (MRS) of the brain and
31P MRS and saturation transfer of resting skeletal muscle were used to
investigate intracellular metabolites and fluxes through the creatine kinase
(CK) reaction in a patient with the syndrome of mitochondrial myopathy,
encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Acute
cortical lesions were characterized by severely elevated lactate levels and
reduced concentrations of N-acetylaspartyl compounds, glutamate, and
myo-inositol. Similar but less extreme alterations were also observed in gray
matter regions that appeared normal on magnetic resonance images. In-
vestigation of the gastrocnemius muscle at rest demonstrated a reduced
phosphocreatine level, elevated concentrations of inorganic phosphate and
free adenosine 58-diphosphate, and an abnormally low phosphorylation po-
tential. Besides a moderately increased muscular phosphocreatine concen-
tration, none of the metabolic disturbances detected on MRS improved with
oral creatine supplementation. Forward and reverse fluxes through the CK
reaction did not significantly change upon creatine treatment. Follow-up
MRS investigations may thus provide objective markers of treatment re-
sponse in vivo without the hazards or inconvenience of biopsy.
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A point mutation at base pair 3243 or 3271 of the
mitochondrial transfer RNA (tRNA)Leu(UUR) gene is
most frequently the underlying cause of the mater-
nally inherited syndrome of mitochondrial myopa-
thy, encephalopathy, lactic acidosis, and strokelike
episodes (MELAS).29 Common biochemical defects
observed at muscle biopsy are impaired complex I or
IV activities or multiple defects of respiratory chain-
ing enzymes. The disease is characterized clinically
by strokelike episodes associated with cerebral in-
farctions on magnetic resonance imaging (MRI) of
the head; seizures; hemiparesis; visual loss; and pro-
gressive dementia, headaches, vomiting, and muscle
weakness accompanied by accumulation of lactate. It
is assumed that the infarcts are nonvascular and are
due to transient oxidative-phosphorylation dysfunc-
tion within the brain parenchyma. The clinical
course is variable, with patients becoming progres-
sively disabled in a stepwise fashion. Therapeutic
drug trials aim at the improvement of aerobic energy
production and prevention of acidosis-related dam-
age. However, their effectiveness is difficult to assess
in view of the diversity of clinical manifestations and
the fluctuating nature of the clinical course.
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(MRS) permits the noninvasive investigation of
metabolic abnormalities in human tissues in vivo. In
MELAS patients, previous proton MRS studies of the
brain have demonstrated an elevation of the intra-
cellular lactate level and a decreased concentration
of N-acetylaspartyl compounds (NAA; i.e., mostly N-
acetylaspartate with an additional contribution from
N-acetylaspartyl glutamate).4,7,9,10,22,25,35 Phospho-
rus MRS investigations of brain3,12,19 and skeletal
muscle1,19,26,31 have revealed a decreased concentra-
tion of phosphocreatine (PCr), whereas that of in-
organic phosphate (Pi) was elevated. Unlike muscle
biopsy, MRS permits noninvasive monitoring of
treatment and may be a potentially useful tool for
assessing therapeutic efficacy. In patients with pri-
mary mitochondrial disorders, serial 1H MRS exami-
nations have demonstrated a decline of intracerebral
lactate levels during treatment with sodium dichlo-
roacetate.11,21,25 Using skeletal muscle 31P MRS, evi-
dence for improved cellular energy state has been
obtained in a MELAS patient following administra-
tion of riboflavin and nicotinamide.26
Recently, Hagenfeld et al.16 reported reduced
frequency and intensity of headaches and improve-
ment of work performance in a MELAS patient dur-
ing creatine (Cr) treatment. In normal subjects, it is
well established that high-dose Cr intake for several
days may elevate skeletal muscle Cr and PCr levels18
and improve performance during high-intensity, in-
termittent exercise.15 This beneficial effect was pos-
tulated to be due to higher pre-exercise PCr stores
and an improved PCr resynthesis capacity.15 To
study the physiological mechanisms underlying po-
tentially beneficial effects of oral Cr supplementa-
tion, we used 31P MRS for monitoring the therapeu-
tic response in a girl with MELAS. Resting muscle
intracellular phosphates and fluxes through the cre-
atine-kinase (CK) reaction were repeatedly investi-
gated by static spectroscopy and saturation-transfer
(ST) measurements. In parallel, additional 1H spec-
tra of the brain were recorded before and 9 weeks
after initiation of Cr treatment.
MATERIALS AND METHODS
Case Report. Our patient is a 14-year-old girl, the
third child of nonrelated parents. Her siblings are
healthy. Pregnancy and birth were uneventful, and
the milestones of development were reached within
the normal range. At the age of 9 years, epilepsia
partialis continua with continuous twitches of the
right face, arm, and leg occurred, accompanied by
severe headache and “eye blinking” of the left eye.
“Eye blinking” was the description given by the pa-
tient with reference to continuous visual flashes of
lightning. The girl was functionally blind in her left
eye. Electroencephalography showed continuous
spikes in the left precentral and occipital region.
Although resistant to all medical therapeutic trials
with conventional antiepileptic drugs, the seizures
stopped spontaneously after some days. They were
followed by a Todd’s paresis that lasted for several
days. Lactate level was elevated in the cerebrospinal
fluid and plasma. A point mutation at base pair
3243 of the mitochondrial tRNALeu(UUR) indicated
MELAS syndrome. Therapeutic trials were started
with thiamine, riboflavine, coenzyme Q10, and carni-
tine. Finally, Cr monohydrate at a dose of 5 g/day
(body weight, 24 kg) was introduced for 10 weeks.
All treatments were tolerated well, but none was suc-
cessful in eliminating plasma lactate or seizure activ-
ity. The epileptic syndrome was resistant to all anti-
epileptic drugs. The patient is now receiving
lamotrigine and phenobarbital, with blood levels in
the therapeutic range. She is unable to walk alone, is
blind, and has developed sensorineural hearing loss.
She has to be tube-fed.
Magnetic Resonance Imaging. All MRI examina-
tions were performed at 1.5 T (Magnetom 63SP;
Siemens, Erlangen, Germany). The study was con-
ducted according to the Declaration of Helsinki af-
ter informed written consent had been obtained.
Conventional spin-echo sequences were employed
for MRI. An axial double-echo proton-density and
T2-weighted sequence (repetition time, TR 2700 ms;
echo times, TE 15/90 ms; acquisitions, Acq 1; matrix
192 × 256; acquisition time, TA 8:42 min) and a
coronal T1-weighted sequence (TR/TE 450/15 ms;
Acq 2; matrix 256 × 256; TA 3:55 min) were per-
formed. The field of view was 230 mm.
The first MRI study, which was performed before
Cr treatment, showed multiple, mainly cortical, de-
fects located in the cerebellar vermis, the right cer-
ebellar hemisphere, the right occipital lobe, and the
right parietal lobe. Furthermore, symmetric defects
of the pallidum were found. The T2-weighted im-
ages showed edematous swelling of the cortex and
mainly subcortical white matter of the right parieto-
occipital operculum extending into the dorsal pari-
etal cortex and of the left parietal operculum. These
lesions showed only mild signal loss on T1-weighted
images resulting in a pseudothickening of the cor-
tex. The follow-study after 9 weeks of Cr treatment
showed the same defects without any changes (Fig.
1). The opercular lesion on the left had resolved
without any definite defect, the right opercular le-
sion resulted in small bright area on T2-weighted
images, possibly resembling a gliotic defect smaller
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than the original lesion. However, a new left occipi-
tal lesion including the left calcarine fissure and ex-
tending into the parietal and paramedian cortex had
evolved. The MRI changes of the new lesion re-
sembled the acute opercular lesions of the first
study. Pseudoterritorial lesions resulting only par-
tially in defects on follow-up studies are common
and quite typical in patients with MELAS. The sym-
metric defects of the basal ganglia resemble those
seen after cerebral anoxia and may be considered
evidence of a previous episode of a more global ce-
rebral energy crisis in this patient.
1H Spectroscopy. Proton spectra were recorded
with the standard imaging head coil immediately fol-
lowing the MRI examinations. Two 8-ml volumes of
interest (VOI) with predominantly gray matter, one
centered in the right opercular cortex and the other
midline in the occipital cortex (Fig. 2) were repeat-
edly investigated 4 days before initiating Cr treat-
ment and 9 weeks thereafter. All spectra were re-
corded applying the STEAM (stimulated echo
acquisition mode)13 technique (TR/TE 3000/20 ms;
1-K complex data points, Acq 128).
31P Spectroscopy. An 80-mm diameter surface coil
was employed for 31P MRS studies. A baseline exami-
nation was performed immediately before initiation
of Cr treatment (4 days after the first 1H MRS study)
and a second one after 10 weeks (9 days after the
second 1H MRS study) on the last day of Cr treat-
ment. Spectra were recorded mainly from the gas-
trocnemius muscle with a pulse-and-acquire tech-
nique (average flip angle 50°, TR 5 s, 1-K complex
data points, Acq 32). An initial static spectrum
served for measuring steady-state peak areas and po-
sitions. For kinetic measurements, selective satura-
tion of the resonance of either PCr or the g-phos-
phate of adenosine 58-triphosphate (g-ATP) was
achieved by a DANTE (delays alternating with nuta-
FIGURE 1. Axial T2-weighted spin-echo images (TR/TE 2700/90
ms; slice thickness, 6 mm) obtained during Cr treatment (second
MRI examination). (A) Image from the level of the basal ganglia
showing the symmetric pallidal and the right occipital defects as
well as the acute cortical lesion of the left occipital lobe. Note the
high intensity of the optic radiation, possibly resembling gliotic
changes. (B) Slice, located 3 cm more cranially, demonstrating
cortical swelling within the left parietal and paramedian cortex as
well as localized subcortical edema.
FIGURE 2. T2-weighted images and results obtained with 1H
MRS (TR/TE 3000/20 ms; Acq 128). Boxes indicate VOIs se-
lected for spectroscopy. The spectra show metabolite reso-
nances from mobile lipids (Lip), lactate (Lac), NAA, glutamate
(Glu), glutamine (Gln), tCr, choline compounds (Cho), and myo-
inositol (Ins). Brain MRI and MRS changes in the right parieto-
occipital operculum: (A) strokelike lesion with abnormal T2 pro-
longation (pretreatment), which appears mostly normal (C) after 9
weeks (during Cr treatment) and corresponding spectra from the
VOI recorded (B) before and (D) during Cr treatment. Changes at
MRI and MRS in the occipital region: (E) normal-appearing gray
matter (pretreatment) and (G) acute strokelike lesion in the left
occipital cortex (during Cr treatment) and corresponding 1H spec-
tra from the midline VOI obtained (F) before and (H) during Cr
treatment.
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tions for tailored excitation)24 pulse train (25 hard
pulses of 200-µs duration, 2-ms interpulse delay).
Each of these ST series consisted of nine spectra with
different intervals t (mixing time) between the
DANTE and the readout pulse (27 ms < t < 4025
ms). Finally, a single spectrum was recorded (t = 27
ms) after shifting the frequency of the DANTE satu-
ration scheme “to the left” of the PCr resonance by
an increment equivalent of the separation of the PCr
and g-ATP peaks (Dn = +62 Hz; “mirror irradiation”)
for evaluation of radiofrequency spillover effects.
Data Analysis. Automated quantification of the 1H
MRS data to obtain absolute metabolite concentra-
tions was performed by LCModel27 using a data base
of calibrated model spectra. Previously recorded 1H
spectra (unpublished data) of normal cortical gray
matter from six children (mean age, 14.3 years;
range, 10–17 years) served as a basis for comparison.
Processing of the 31P data included zero-filling to
2 K, exponential multiplication (5-Hz line broaden-
ing), Fourier transformation, and Lorentzian line fit-
ting23 to determine resonance positions and areas.
The pH was calculated from the chemical-shift dif-
ference between Pi and PCr,
32 and the intracellular
free Mg2+ concentration, [Mg2+], was computed us-
ing the chemical shifts of the a- and b-phosphate of
ATP (a-ATP, b-ATP).36 To obtain concentration es-
timates, the peak area of the b-ATP resonance was
used as a reference and assumed to represent a cy-
tosolic ATP level of 8.2 mmol/L.17 Functional mito-
chondrial status was assessed from the concentration
of cytosolic free adenosine 58-diphosphate (ADP),
the phosphorylation potential (PP), defined as
[ATP]/([ADP] × [Pi]), and the ratio of the mito-
chondrial ATP synthesis rate over its maximum value
according to V/Vmax = 1/{1 + (0.53 × [PCr]/[Pi])}.
8
In skeletal muscle, ADP is micromolar and, hence,
below the sensitivity of in vivo 31P MRS. Therefore,
ADP levels and V/Vmax were computed from the CK
reaction:




Cr + MgATP2- ,
(1)
by exploiting the metabolite ratio Pi/PCr as advo-
cated by Chance et al.8 For comparison, reference
31P spectra of the resting calf muscle were taken
from a previous study (unpublished data) in nine
healthy volunteers (mean age, 26.8 years; range, 21–
33 years).
A detailed description of the ST technique and
its underlying theory, including a thorough analysis
of the experimental limitations, is presented in a
separate publication.34 Briefly, pseudo–first-order
rate constants for the exchange of phosphate be-
tween ATP and PCr through the CK reaction, can be
defined as k+1 = kfor × [ADP] × [H
+] and k−1 = krev ×
[Cr]. The corresponding fluxes are therefore given
by vfor = k+1 × [PCr] and vrev = k−1 × [ATP]. The
time-dependent behavior of the PCr and the g-ATP
signals during the ST experiment are dependent on
k+1 and k−1. Hence, the pseudo–first-order rate con-
stants are obtained by plotting the peak areas of both
resonances as a function of the mixing time for both
ST experiments (i.e., the one in which the PCr signal
is saturated and another in which g-ATP is saturated)
and simultaneous fitting of all four time courses us-
ing nonlinear least-squares regression. Reference
data for the normal resting calf muscle were ac-
quired in three healthy volunteers (mean age, 31.3
years; range, 31–32 years).
Differences between patient and control data
were regarded as significant on the 1%, 0.01%, or
0.0001% level if they exceeded 2.5×, 4×, or 5× the
standard deviation (SD) in the control group.
RESULTS
1H Spectroscopy. Figure 2 shows brain spectra
from repeated investigations of the two VOIs. A dou-
blet signal (splitting of 7 Hz) from intracerebral lac-
tate at 1.33 ppm, which is not readily detected by 1H
MRS at 1.5 T in normal brain, was clearly visible in all
patient spectra. Metabolite concentrations are sum-
marized in Table 1. Before Cr treatment, an acute
strokelike lesion was found in the right parieto-
occipital operculum (Fig. 2A). The spectrum from
this area (Fig. 2B) indicates an extreme elevation of
lactate and reduced NAA (31% of the mean control
value). In addition, glutamate and myo-inositol were
reduced, whereas the levels of other metabolites,
such as glutamine, total creatine (tCr, i.e., Cr plus
PCr), and choline compounds, were normal. After 9
weeks, the lesion had almost resolved (Fig. 2C). In
the corresponding spectrum (Fig. 2D), the area of
the lactate signal was markedly reduced (22% of the
value of the first examination), though it was still
abnormal. Additionally, NAA partly recovered (to
53% of normal) but still remained below control
levels. Similar findings, that is, elevated lactate and
decreased NAA (55% of the mean control value)
plus reduced glutamate and myo-inositol, were ob-
served in a 1H spectrum (Fig. 2F) acquired midline
in the occipital cortex. Note that this location ap-
peared normal at the first MRI examination (Fig.
2E), whereas a strokelike episode occurred during
Cr treatment (Fig. 2G). The corresponding 1H spec-
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trum from the second examination (Fig. 2H) dem-
onstrated a large increase in lactate (210% of the
initial value) and progressive reduction of NAA (to
49% of normal).
Static 31P Spectroscopy. Table 2 gives a summary
of metabolic parameters extracted from 31P spectra
without ST. The level of free intracellular Mg2+ and
the cytosolic pH were within the normal range and
did not change significantly upon Cr treatment. In
the baseline examination, PCr was only 80% of the
mean control value, whereas Pi was elevated at 153%.
The estimated free ADP concentration was increased
at 191% with a concomitant elevation in V/Vmax
(165% of the mean control value). The phosphory-
lation potential was well below the minimum value
found in the control group (135 mmol−1) and was
38% of the mean control value. At the end of Cr
treatment, PCr was increased by 11% but still did not
reach the mean control level (89%). None of the
other markers of an abnormal energy metabolism
showed a trend towards normalization: Pi, ADP, and
V/Vmax progressively increased as compared with
the mean control values (260%, 279%, and 204%,
respectively), whereas the phosphorylation potential
further declined (21%).
Kinetic Investigations. Saturation-transfer 31P
spectra from the patient’s calf muscle are presented
in Figure 3. Kinetic parameters extracted from fit-
ting the data are given in Table 3. The rate constants
k+1 and k−1 and the fluxes vfor and vrev were some-
what higher than in the control group (167%, 157%,
135%, and 157%, respectively) although only the dif-
ferences for k−1 and vrev were significant. None of the
kinetic parameters was significantly affected by Cr
treatment.
DISCUSSION
Our combined findings from 1H an 31P MRS under-
line the marked involvement of both brain and skel-
etal muscle in mitochondrial dysfunction. Results
from proton spectroscopy coincide with previous ob-
servations in MELAS patients. The generalized in-
crease in lactate may be ascribed to abnormal up-
regulation of glycolytic activity throughout the brain,
including regions that appear normal on MRI. This
is consistent with impairment of oxidative phosphor-
ylation due to defective mitochondrial complex I.
N-acetyl-L-aspartate is synthesized in brain mitochon-
dria from acetyl-CoA and aspartate and is believed to
be present primarily in neurons. The decline in NAA
seen in MELAS patients is therefore attributed to
neuroaxonal damage. This is further supported by
the accompanying decrease of glutamate by an
amount similar to that of NAA, which was also ob-
Table 2. Cytosolic phosphate metabolite ratios and







PCr/ATP 3.53 ± 0.19 2.81* 3.12
Pi/ATP 0.55 ± 0.08 0.84* 1.42
†
Pi/PCr 0.16 ± 0.02 0.30
† 0.45†
[PCr] mmol/L−1 28.9 ± 1.5 23.0* 25.6
[Pi] mmol/L
−1 4.5 ± 0.7 6.9* 11.7†
[ADP] µmol/L−1 8.9 ± 1.3 17.0† 24.8†
[Mg2+] mmol/L−1 0.9 ± 0.3 1.6 1.5
pH 7.04 ± 0.02 7.09 7.01
PP mmol−1 204 ± 64 78 42*
V/Vmax 0.23 ± 0.03 0.38
‡ 0.47†
*Beyond ±2.5 SDs (i.e., P < .01) of the mean value in controls.
†Beyond ±5 SDs (i.e., P < .000001) of the mean value in controls.
‡Beyond ±4 SDs (i.e., P < .0001) of the mean value in controls.





Parieto-occipital operculum Occipital cortex
Baseline On treatment Baseline On treatment
Lactate <1.0 14.1* 3.1† 5.0* 10.5*
NAA 11.8 ± 1.4 3.6* 6.3‡ 6.5‡ 5.8†
Glutamate 11.0 ± 2.3 4.4‡ 7.4 3.9‡ 6.7
Glutamine 4.9 ± 1.2 6.0 4.6 5.7 5.0
tCr 6.9 ± 0.9 4.8 6.5 6.0 6.8
Choline 1.1 ± 0.1 1.4 1.2 1.3 1.2
Myo-inositol 5.6 ± 0.3 2.6* 5.4 3.6* 3.2*
*Beyond ±5 SDs (i.e., P < .000001) of the mean value in controls.
†Beyond ±4 SDs (i.e., P < .0001) of the mean value in controls.
‡Beyond ±2.5 SDs (i.e., P < .01) of the mean value in controls.
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served by Wilichowski and colleagues.35 Bates et al.5
demonstrated that partial inhibition of single com-
plexes of the respiratory chain can result in de-
creased NAA production. Impaired mitochondrial
function may thus contribute to the observed reduc-
tion in NAA without cell death.
Metabolic alterations are considerably pro-
nounced in MRI-detectable lesions. Extensive accu-
mulation of lactate is indicative of a severe energy
failure and acute hypoxia during a strokelike epi-
sode.35 This may, in turn, cause neuronal dysfunc-
tion, as evidenced by further reduction in NAA.
Similar to previous observations,10 transient recovery
of NAA and regression of the original lesion at MRI
were found in serial investigations (Figs. 2A–2D).
This may indicate changes in intracellular NAA as a
result of a reversible impairment of mitochondrial
function, consistent with the above hypothesis of a
decreased NAA production due to defective respira-
tory chain complex. Comparing the time courses of
metabolic changes in both VOIs, the possibility that
the transient recovery of NAA and decline of lactate
observed in the parieto-occipital operculum were re-
lated to Cr treatment may be discounted because the
opposite trends were found in occipital cortex. This
also indicates that evaluation of a single VOI is
insufficient for reliably assessing response to
therapy.
The cellular ATP concentration at rest is tightly
regulated and was found to be unaffected upon Cr
Table 3. Pseudo–first-order rate constants and fluxes for the







−1 0.39 ± 0.13 0.65 0.53
k−1 s
−1 0.99 ± 0.09 1.55* 1.59*
k−1/k+1 2.6 ± 0.6 2.4 3.0
vfor mmol/L
−1s−1 11.1 ± 3.1 15.0 13.6
vrev mmol/L
−1s−1 8.1 ± 0.7 12.7* 13.0*
*Beyond ±5 SDs (i.e., P < .000001) of the mean value in controls.
FIGURE 3. Examples of 31P spectra measured during Cr treatment in the resting gastrocnemius muscle using different mixing times t
after saturation of (A) g-ATP or (B) PCr. The center frequency of the selective saturation pulse is marked by an asterisk. The spectra
comprise resonances of a- (−7.49 ppm), b- (−15.72 ppm), and g-ATP (−2.37 ppm), PCr (0.00 ppm), Pi (4.84 ppm, corresponding to a pH
of 7.01), phosphomonoesters (PME, 7.09 ppm), and phosphodiesters (PDE, 2.51 ppm).
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supplementation.18 The assumption of a normal
ATP level has also been verified at muscle biopsy in
single cases of mitochondrial myopathies.19,31
Therefore, using PCr/ATP and Pi/ATP to calculate
PCr and Pi concentrations seems justified. Qualita-
tively and quantitatively, our 31P MRS investigations
of the resting gastrocnemius muscle revealed typical
features observed in patients with mitochondrial my-
opathies,2 including elevated ADP and Pi coupled to
reduced PCr. Again, these abnormalities reflect the
inability of the mitochondria to efficiently utilize
oxygen for ATP synthesis. Phosphocreatine and ADP
are interrelated via the CK reaction (Eq. 1), which is
activated by a rising level of ADP to restore ATP.8
Mitochondrial activity determines the phosphoryla-
tion potential, which is low, indicating a low energy
reserve in the resting muscle. Finally, defective mi-
tochondrial functionality is apparent in an abnormal
transfer function for ADP control given by an in-
creased V/Vmax, which points to accelerated ATP
production in functioning mitochondria to fulfill
the energy demands of the cell.3,12 The rise in the
resting muscle PCr by 11% upon Cr supplementa-
tion is at the lower end of increases observed in pre-
vious studies of healthy volunteers.20,30,33 Besides the
moderately increased PCr availability, Cr treatment
did not improve any of the other parameters char-
acterizing muscular energy status at rest (Table 2).
Our kinetic parameters from the control group
describing flux through the CK reaction for the di-
rection of ATP synthesis are within the range of pre-
vious literature results.14,28 The corresponding re-
verse reaction has not yet been investigated in
human muscle. Consistent with findings in animals,6
the ratio k−1/k+1 was approximately 3. Fluxes vfor and
vrev were similar, suggesting near-equilibrium condi-
tions of the CK reaction. It should be noted that
kinetic parameters of the resting muscle do not ad-
equately describe conditions of work or recovery
from exercise.
An increased concentration of cytosolic ADP, as
found in our patient (Table 2), would lead to a
higher pseudo–first-order rate constant k+1 consis-
tent with the observed trend (Table 3). A similar
effect on k−1 might result from an increased avail-
ability of free Cr. However, as the CK reaction is near
equilibrium in resting muscle (see above discus-
sion), PCr resynthesis should not be limited by the
CK reaction under out experimental conditions;
hence, variations in Cr per se should not lead to
pronounced changes in the CK kinetics. This is in
keeping with our observation that Cr treatment did
not produce significant effects on the unidirectional
CK reaction rates and fluxes.
In summary, there was no clinical improvement
from Cr treatment in our patient. Consistently, ex-
cept for a slightly elevated intramuscular PCr con-
centration, no further beneficial effect on various
parameters of cellular energy metabolism could be
found with static or kinetic investigations using 31P
MRS. Cerebral metabolic disturbances and their
progress with time observed with 1H MRS were typi-
cal for MELAS without demonstrating indications of
a beneficial influence from Cr treatment. In conclu-
sion, follow-up MRS studies are capable of providing
objective markers of treatment response in mito-
chondrial myopathies in vivo without the potential
damage inflicted by biopsy. This is particularly im-
portant because of the necessarily limited number of
patients with such rare disorders that can be studied
with any given protocol.
A portion of this work was presented at the 8th scientific meeting
of the International Society for Magnetic Resonance in Medicine
in April 2000, Denver, Colorado.
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